Investigating how SGLT2 inhibitors affect heart health in women with HIV
Effects of SGLT2 Inhibition on Coronary Flow Reserve and Other Key Indices Relevant to Type 2 Myocardial Infarction Risk among Women with HIV
This study is looking at how a type of medication called SGLT2 inhibitors can help protect the hearts of women living with HIV who are at risk for heart attacks, and it will involve giving some women the medication and others a placebo to see how it affects their heart health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11006470 on NIH RePORTER |
What this research studies
This research focuses on women living with HIV who are at a higher risk of heart attacks. It aims to explore how a specific class of medications, known as SGLT2 inhibitors, can improve heart function and reduce risks associated with type 2 myocardial infarction. The study will involve a randomized controlled trial where participants will receive either the medication or a placebo, and their heart health will be monitored using advanced imaging techniques. By understanding the effects of these medications, the research seeks to identify new ways to protect heart health in this vulnerable population.
Who could benefit from this research
Good fit: Ideal candidates for this research are women living with HIV who are on antiretroviral therapy and at risk for myocardial infarction.
Not a fit: Patients who are not living with HIV or those who do not have risk factors for myocardial infarction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved heart health and reduced risk of heart attacks for women living with HIV.
How similar studies have performed: Previous research has shown that SGLT2 inhibitors can improve heart function in certain populations, but this specific application in women with HIV is novel.
Where this research is happening
Boston, United States
- Massachusetts General Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Zanni, Markella V. — Massachusetts General Hospital
- Study coordinator: Zanni, Markella V.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.